Unlocking this potential can only be done with partners

Our platform opens up nearly limitless possibilities for the production of a wide range of chemical compounds. Initially, we are focusing on low-quantity, high-value products typically associated with pharmaceuticals, such as the active ingredients in medicines. In parallel, we are exploring opportunities in nutraceuticals, which include food, flavor, and fragrance compounds. These markets share dynamics similar to pharmaceuticals but offer a faster time-to-market when producing naturally occurring compounds classified as Generally Recognized As Safe (GRAS), bypassing the need for FDA approval.

Additionally through multiple grants, the US Department of Energy has invested in the development of biofuels on our platform, specifically Isobutanol for Sustainable Aviation Fuel.

The more partners, the better

With a leadership team very experienced in biotech startups, we recognize the limitations of tackling multiple markets on our own. We neither have the workforce nor the capital to independently address the vast array of opportunities our platform enables. By working with the right partners, we can accelerate the commercialization and scaling of sustainable biosolutions based on exozymes.

So to unlock the full potential of our platform, collaboration is key. We are a true platform company, and for each use case, we aim to partner with organizations that have deep expertise in specific markets and products. These partnerships are essential to ensure that our solutions are not only scientifically advanced but also commercially viable.

We also see tremendous potential for partnerships within the synthetic biology (SynBio) community. Our technology offers the ability to finally scale SynBio projects that have struggled to achieve commercial success.  As such, we see our platform as  an extension - the next logical step for most SynBio projects.

Together with our partners, we can revolutionize industries and bring groundbreaking solutions to market faster and more effectively.

Creating value for partners through exozyme biosolutions

Our CEO, Michael Heltzen, explains how to create value with exozymes, including different models of partnering.

Partnership models

Licensing

This is typically for partners in mature markets where they replace their small molecule production, either entirely or parts of it. These partners who pay a license fee to use our technology.

Joint venture

Likely the most frequent setup initially will be a joint-venture, where another company and us go together and form a new subsidiary to address a specific market. We each bring critical components to table, that enable a sum better than its parts.

Spin-outs

If we identify an opportunity that we wish to mature, we can set up an internal team that tackles a specific challenge with an addressable market. Eventually we will spin out this wholly owned subsidiary to form its own company.